BioSpace News Archive

Company is now preparing a Series B funding round to finance the Phase 2 clinical program

Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States

To Assess the Potential of Non-Opioid Treatment Options for Chronic Pain, Study Evaluates Pain Relief, Patient Function and Satisfaction

Recipharm, the contract development and manufacturing organisation, has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early stage development through to commercial manufacturing.

Factory-CRO Group, a leading global contract research organization, is pleased to announce Sapna Hornyak as its new president and CEO and the appointment of Nick Thornton to chairman of its board of directors.

ADL Bionatur Solutions advances the results of selected key performance indicators for the first quarter of 2019 ending March 31, 2019.

The Global Health Investment Fund (GHIF) and Medicines Development for Global Health (MDGH) announced the sale of MDGH’s Priority Review Voucher (PRV).

Three Researchers Awarded $250,000 Each to Advance Independent Research in Cardiac Diseases

Vericel Corporation announced that it has entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid® in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue.

Esperion announced that the company will host an analyst and investor day on Thursday, May 30, 2019, beginning at 9:00 a.m. Eastern Time.